VIVOZON

Vivozon is working to extend its pipeline of second generation analgesic medication candidates, as well as its target combination of third analgesic drug opportunities. Vivozon creates new chemical medications with synergistic efficacy by acting on several targets. People derive candidate substances with potential for successful phase 2 clinical trials by applying efficacy based screening from the early stages of discovery, and they continue with global clinical development clinical trials as ... a single dose injectable for treating postoperative pain, which will be expanded to various indications such as neuropathic pain and cancer pain by multiple administration routes makes bold funding for research and education, developing its pipeline to include treatments for central nervous system illnesses like addiction, dementia, depression, and disease.More